GALNT14 genotype as a response predictor for concurrent chemoradiotherapy in advanced esophageal squamous cell carcinoma

Abstract

Esophageal squamous cell carcinoma is an aggressive cancer. We investigated genetic response predictors for patients with advanced esophageal squamous cell carcinoma receiving concurrent chemoradiotherapy. A cohort of 108 patients was recruited. Survival analysis showed that lower esophageal location of tumor, more advanced metastasis stage, and longer length of tumor were associated with poorer overall survival (adjusted P = 0.001, < 0.001, and 0.045, respectively), while the presence of complete/partial response to concurrent chemoradiotherapy was independently associated with better overall survival (adjusted P < 0.001). The GALNT14-rs9679162 “GG” genotype was associated with a lower rate of response (P = 0.014). Multivariate Cox-proportional hazards models also showed that the “GG” genotype was associated with a longer time to complete/partial response (adjusted P = 0.022), independent of leukocyte counts and gender. In conclusion, the presence of a complete/partial response to chemoradiotherapy was critical for advanced esophageal squamous cell carcinoma patients to achieve better overall survival. The GALNT14-rs9679162 “GG” genotype was associated with a longer time to complete/partial response of concurrent chemoradiotherapy.

Prognostic Stratification of Advanced Gastric Signet Ring Cell Carcinoma by Clinicopathological Factors and GALNT14 Genotype

“…GALNT14 has also been identified as a neuroblastoma predisposition gene 11 . To date, GALNT14-rs9679162 genotype has been demonstrated to be an effective outcome predictor in multiple gastrointestinal cancers including hepatocellular carcinoma, cholangiocarcinoma, esophageal cancer and colorectal cancer especially with mucinous histology 12 - 15 . Here, we hypothesized that GALNT14-rs9679162 genotype might also associate with the outcome of gastric SRCC.…”

Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation

“…The intragenic heterozygous deletion in GALNT14 identified in patient 1 was inherited from a healthy father and as GALNT14 has not previously been implicated in human disease, the deletion was considered as of uncertain significance. GALNT14 is important during embryonal development, and its relevance in cancer and cancer therapy is being investigated (Lin et al, 2016;Mariano et al, 2015;Tsou et al, 2017). GALNT14 overexpression increases mRNA expression of N-cadherin (Huanna et al, 2015), which is a cell adhesion protein with an important role in asymmetric cell-formations in the dorsal mesentery (Davis et al, 2008;Plageman, Zacharias, Gage, & Lang, 2011;Welsh et al, 2013).…”

GALNT14: An Emerging Marker Capable of Predicting Therapeutic Outcomes in Multiple Cancers

“…However, CCRT has a high-toxicity profile which restricts its clinical use. In order to select a suitable patient group for CCRT, the GALNT14-rs9679162 SNP has been examined as a therapeutic response predictor in ESCC [27]. A cohort of 108 patients with ESCC receiving CCRT was recruited.…”

“…Previous studies of the predictive role of the GALNT14-rs9679162 SNP showed that in HCC and esophageal cancer ("carcinoma"), patients with the "TT" genotype have a better prognosis, whereas in other cancers ("adenocarcinoma"), patients with the "GG" genotype have better outcomes [19,22,27,29,33,35,37]. Since GALNT14 enzyme levels have been associated with cancer characteristics, it can be speculated that GALNT14 enzyme expression levels are associated with different SNP genotypes.…”